Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2000
Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
K F Nolan, C O Yun, Y Akamatsu, et al.
Breast Cancer Research and Treatment
|
March 30, 2007
Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
Y Wang, F Ylera, M Boston, et al.
Leukemia Research
|
September 17, 2005
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing
H B Koon, P Severy, D S Hagg, et al.
Cancer Research
|
May 15, 1989
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity
R W Kozak, A Raubitschek, S Mirzadeh, et al.
Cancer Gene Therapy
|
April 16, 2016
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
S C Katz, G R Point, M Cunetta, et al.
International Immunology
|
July 31, 2007
Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML)
W Yang, E L Beaudoin, L Lu, et al.
Journal of Hematotherapy
|
October 1, 1995
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
S M Chamow, D Zhang, X Y Tan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 1, 1994
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
S M Chamow, D Z Zhang, X Y Tan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 1, 1991
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival
P S Brown, G L Parenteau, F M Dirbas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1989
A humanized antibody that binds to the interleukin 2 receptor
C Queen, W P Schneider, H E Selick, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2000
Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
K F Nolan, C O Yun, Y Akamatsu, et al.
Breast Cancer Research and Treatment
|
March 30, 2007
Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
Y Wang, F Ylera, M Boston, et al.
Leukemia Research
|
September 17, 2005
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing
H B Koon, P Severy, D S Hagg, et al.
Cancer Research
|
May 15, 1989
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity
R W Kozak, A Raubitschek, S Mirzadeh, et al.
Cancer Gene Therapy
|
April 16, 2016
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
S C Katz, G R Point, M Cunetta, et al.
International Immunology
|
July 31, 2007
Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML)
W Yang, E L Beaudoin, L Lu, et al.
Journal of Hematotherapy
|
October 1, 1995
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
S M Chamow, D Zhang, X Y Tan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 1, 1994
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
S M Chamow, D Z Zhang, X Y Tan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 1, 1991
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival
P S Brown, G L Parenteau, F M Dirbas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1989
A humanized antibody that binds to the interleukin 2 receptor
C Queen, W P Schneider, H E Selick, et al.
Page
of 7